Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers

AIMS: To evaluate the safety, pharmacokinetics and pharmacodynamics of single‐ and multiple‐rising doses (MRDs) of BI 705564 and establish proof of mechanism. METHODS: BI 705564 was studied in 2 placebo‐controlled, Phase I clinical trials testing single‐rising doses (1–160 mg) and MRDs (1–80 mg) of...

Descripción completa

Detalles Bibliográficos
Autores principales: Litzenburger, Tobias, Steffgen, Jürgen, Benediktus, Ewald, Müller, Fabian, Schultz, Armin, Klein, Elliott, Ramanujam, Meera, Harcken, Christian, Gupta, Alpana, Wu, Jing, Wiebe, Sabrina, Li, Xiujiang, Flack, Mary, Padula, Steven J., Visvanathan, Sudha, Hünnemeyer, Andreas, Hui, Jianan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290462/
https://www.ncbi.nlm.nih.gov/pubmed/32986868
http://dx.doi.org/10.1111/bcp.14571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290462/
https://www.ncbi.nlm.nih.gov/pubmed/32986868
http://dx.doi.org/10.1111/bcp.14571

Ejemplares similares